Amneal Pharmaceuticals, Inc. announced the approval and launch of fluorometholone ophthalmic suspension. The product received 180-day competitive generic therapy exclusivity from the U.S. Food and Drug Administration, a status that applies to first-marketed generics of key medicines. FML® suspension is indicated for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.